Pharvaris (NASDAQ:PHVS) Stock Price Down 7.4% – Should You Sell?

Pharvaris (NASDAQ:PHVS)’s stock price fell 7.4% on Wednesday . The stock traded as low as $19.00 and last traded at $19.00. 26,143 shares traded hands during trading, a decline of 70% from the average session volume of 86,941 shares. The stock had previously closed at $20.51.

Analyst Upgrades and Downgrades

Separately, Oppenheimer upped their price target on Pharvaris from $38.00 to $42.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Pharvaris presently has an average rating of “Moderate Buy” and a consensus price target of $33.60.

Pharvaris Stock Performance

The business has a 50-day moving average of $20.77 and a two-hundred day moving average of $19.29.

Institutional Trading of Pharvaris

A number of institutional investors and hedge funds have recently modified their holdings of PHVS. Public Employees Retirement System of Ohio acquired a new stake in Pharvaris during the third quarter worth $57,000. Barclays PLC acquired a new stake in shares of Pharvaris during the 3rd quarter valued at about $106,000. HighVista Strategies LLC increased its stake in Pharvaris by 35.9% in the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock valued at $422,000 after acquiring an additional 6,018 shares during the period. Jane Street Group LLC acquired a new position in Pharvaris in the third quarter worth about $526,000. Finally, Geode Capital Management LLC lifted its stake in Pharvaris by 18.4% during the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after purchasing an additional 5,753 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.